Fig. 1

Cumulative incidence of all-cause death for nirmatrelvir-ritonavir group vs azvudine group. A Cumulative incidence of all-cause death in the nirmatrelvir-ritonavir group and azvudine group. B Landmark analysis discriminating between all-cause death events occurring before and after 10 days of follow-up. Day 0 (baseline) represents the first day of initiating antivirus treatment. The Kaplan–Meier estimator was used to estimate cumulative incidence, with the log-rank test applied to assess differences between groups